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Key Clinical Message
IgG4-RD can also present in the skeletal muscle, mimicking several other diseases.
It is unusual for this relatively new classification of diseases to present in the mus-
cles and can be mistakenly diagnosed as other autoimmune diseases rendering a
delay in the appropriate management and progression of the disease.
Keywords
Fibro-inflammatory disease, IgG4-related disease, IgG4-associated multifocal
systemic fibrosis, IgG4-positive multi-organ lymphoproliferative syndrome.
Case Report
A 68-year-old lady of an African American descent pre-
sented to the office with complains of unintentional
weight loss of thirty pounds over the last year. She had a
history of follicular lymphoma that had transformed to a
diffuse large B-cell lymphoma (DLBCL) diagnosed more
than 20 years ago. It was treated with eight cycles of
chemotherapy (cyclophosphamide, daunorubicin, vin-
cristine, and prednisone) followed by radiotherapy. She
underwent complete remission with no evidence of recur-
rence until now.
She was noted to have pancytopenia in September
2014. Owing to a concern for the recurrence of lym-
phoma, a positron emission computerized tomography
(PET–CT) was obtained which revealed a mass in her
psoas muscle. Biopsy of the mass showed the presence of
a few macrophages and failed to reveal any evidence of
malignancies or reoccurrence of lymphoma.
The patient then started noticing further weight loss
and decrease in her appetite since, and presented to the
office again after a year. A repeat PET–CT was performed
which demonstrated an overall enlargement of the left
iliac and psoas muscles (Fig. 1). The FDG-uptake
(fluorodeoxyglucose -uptake) along the left rectus femoris
muscle had increased to 12 from the previous value of
9.2. The thickness had also increased to 3 cm from the
previous 2 cm last year. A new area of uptake was also
noted in the left gluteus medius muscle that had an
uptake value of 7.9.
Core biopsy of the masses performed thereafter
revealed fibrosis with sparse lymphocytic infiltrate and
hemosiderin deposition, unremarkable plasma cells, with-
out evidence of a lymphoma (histopathology slides 1–3).
A quantitative IgG was performed that showed a value of
2030 mg/dL (reference range: >19 years of age 700–
1600 mg/dL). IgG4 subclass was also significantly elevated
at 1022 (reference range 7–89). Workup for multiple
myeloma was negative with serum protein electrophoresis
showing a chronic inflammatory pattern and did not
identify a monoclonal protein, but rather a polyclonal
increased in IgG. Other laboratory investigations were as
follows: Creatinine 0.75 mg/dL, LDH 135 U/L, BUN
18 mg/dL; (reference ranges: 0.6–1.1 mg/dL, 140-280 U/L,
7–20 mg/dL, respectively).
The patient was seen in consultation, and a recommen-
dation was made to treat her with steroids after dis-
cussing her case with the pathologist.
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Discussion
Formerly known as IgG4-related systemic disease, IgG4-
related disease (IgG4-RD) is a relatively newly discovered
fibro-inflammatory condition and is named so due to the
presence of antibody subtype IgG4-producing plasma
cells, that are present in large amounts on tissue samples
from involved organs. It has a characteristic histologic
appearance and elevated IgG4 concentrations in the acute
phase of approximately 60–70% of its patients [1, 2]. The
condition can be identified by tumefactive lesions, a dense
lymphoplasmacytic infiltrate rich in IgG4-positive plasma
cells, and storiform fibrosis.
IgG4-RD can virtually occur in any organ of the body
with the most common sites as the salivary glands, peri-
orbital tissues, pancreas, biliary tree, kidneys, lungs,
lymph nodes, breast, aorta, thyroid, prostate, and skin [3,
4]. From our review of literature, this is the second
known occurrence of IgG4-RD in the musculature [5]. In
light of these rare incidences, patients with associated
autoimmune diseases, presenting with myalgias of
unknown origin that may be accompanied by swelling,
Slide 1
Slide 2
Slide 3
Figure 1. PET–CT image of psoas muscle. Histopathology slide 1: Hematoxylin and eosin-stained Psoas muscle biopsy 4009 magnified.
Histopathology slide 2: Immunohistochemistry showing light chain Lambda immunoglobulin 2009 magnified. Histopathology slide 3:
Immunohistochemistry showing Kappa immunoglobulin 2009 magnified.
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discomfort, or general unease in a particular group of
muscle should prompt the physician to include IgG4-RD
in the evaluation of their differentials. The histopathologi-
cal characteristics bear remarkable similarity across organs
regardless of the site of disease, therefore becoming analo-
gous to diseases like sarcoidosis. Several previously known
diseases are now considered to be manifestations of IgG4-
RD: Type 1 autoimmune pancreatitis, mediastinal fibrosis,
K€uttner’s tumor (affects the submandibular glands),
Mikulicz’s disease (involvement of the lacrimal and sali-
vary glands), Riedel’s thyroiditis, Ormond’s disease
(retroperitoneal fibrosis), and inflammatory pseudotumor
are now regarded as forms of IgG4-RD [4].
IgG4-RD has been labeled as a slow condition as usu-
ally symptoms tend to be mild in spite of considerable
organ destruction, if any. People are often described feel-
ing relatively well at the time of diagnosis, although some
may give a history of weight loss. Pain is usually not a
feature of the inflammation but may occur as a secondary
effect due to some form of obstruction or compression. A
diagnosis is often formulated due to the presence of pain-
less swellings or mass lesions that may lead to complica-
tions. Incidental lesions may also be detected on
radiological studies and can be easily misdiagnosed as a
malignancy.
Several genetic studies suggest the involvement of several
human leukocyte antigen (HLA) and non-HLA haplotypes/
genotypes that may be associated with susceptibility to
IgG4-RD or to disease relapse post therapy [6]. Among the
cohort of autoantibodies found to date, autoantibodies
against carbonic anhydrase II and lactoferrin are most com-
monly noted in the serum of IgG4-RD patients [7, 8]. Stud-
ies have shown molecular mimicry between Helicobacter
pylori and constituents of pancreatic epithelial cells suggest-
ing gastric H. pylori infection may set off autoimmune pan-
creatitis in genetically predisposed individuals via cross-
reactivity of the antibodies, yet autoimmunity has not been
completely proved. Antibodies directed against potential
auto-antigens to some degree, may be associated with
systemic manifestations of IgG4-RD [6]. It has also been
postulated that T2-helper cells are a predominant cell
type in IgG4-RD, while transforming growth factor-b
and interleukin-10 have roles in IgG4 class switch and
fibroplasia [6].
Radiographic features are generally nonspecific and
may not provide a reliable distinction between IgG4-RD
and malignancy. A majority of patients with IgG4-RD
have elevated serum IgG4 levels of varying ranges with
approximately 30% of patients having normal serum
IgG4 despite classic histopathological and immunohisto-
chemical features [4, 9]. Data with regard to the use of
serial IgG4 measurement as an indicator of disease activ-
ity is mixed [10]. Despite the reduction of IgG4
concentrations with glucocorticoid treatment in a major-
ity of patients, they still tend to remain above normal val-
ues [9]. Kamisawa et al. [11] demonstrated that IgG4
levels failed to normalize in 63% (115 of 182 patients)
treated with glucocorticoids. It also has been shown that
the disease can remain in remission in some patients
despite persistent elevations of serum IgG4 concentra-
tions, with only 30% of patients having persistent eleva-
tion of serum IgG4 concentrations suffering relapses [11].
Induction and maintenance of remission are the main
treatment goals to prevent progression of fibrosis and
organ damage. All cases of symptomatic IgG4-RD warrant
treatment though some cases of asymptomatic IgG4-RD
may require early management to prevent severe compli-
cations like aoritis, pericarditis, and pachymeningitis [12].
Glucocorticoids are the recommended first-line agents
for induction unless contraindications exist resulting in
rapid improvements of symptoms and a resolution of
radiographic findings. Steroid-induced flares are not
uncommon. Although their efficacy has never been tested
in clinical trials, rituximab, mycophenolate mofetil,
methotrexate, and azathioprine are used frequently as glu-
cocorticoid-sparing agents or remission-maintenance
drugs after glucocorticoid-induced remissions [4, 12].
Other therapeutic possibilities, such as bortezomib, that
are known to target plasma cells, warrant further explo-
ration as well.
Bortezomib, an excellent proteasome inhibitor has been
a novel drug which is currently approved for and used in
the management of relapsed leukemias and multiple
myelomas in the posttransplant setting. Several preclinical
trials showed antimyeloma effects of bortezomib includ-
ing the disruption of the cell cycle and apoptosis induc-
tion, alteration of the bone marrow microenvironment,
and inhibition of nuclear factor kappa B (NFjB) [13].
Due to its unique mechanism of action, bortezomib has
been shown to induce responses in patients with poor
cytogenetics, and in previously refractory patients.
Although clinical trials have yet to be established for the
use of this drug in the management of IgG4-RD, Khan
et al. [14] demonstrated the successful use of bortezomib
in a patient with Hyper IgG4.
Conclusion
IgG4-RD encompasses a large number of medical disor-
ders previously referred to as confined to a single organ.
As a recently recognized condition, links among the
increased quantities of IgG4 plasma cells, varying quanti-
ties of serum IgG4, and its histological features needs to
be determined. Despite being a rare case in itself, to the
knowledge of the authors, this is the second known case
of IgG4-RD to occur in the skeletal muscles.
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